EU/3/18/2045

About

On 31 July 2018, orphan designation (EU/3/18/2045) was granted by the European Commission to Dystrogen Therapeutics S.A., Poland, for ex-vivo fused autologous human bone marrow-derived mesenchymal stem cell with allogenic human myoblast for the treatment of Duchenne muscular dystrophy.

Key facts

Active substance
Ex-vivo fused autologous human bone marrow-derived mesenchymal stem cell with allogenic human myoblast
Disease / condition
Treatment of Duchenne muscular dystrophy
Date of decision
31/07/2018
Outcome
Positive
Orphan decision number
EU/3/18/2045

Review of designation

<p>The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.</p>

Sponsor's contact details

Kasztelanska 49
60-316 Poznan
Poland
Tel. + 48 698 647 783     
E-mail: info@dystrogen.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating